Web7 apr 2024 · "This is a very difficult day for Sage," said company CEO Jeff Jonas on a conference call Tuesday following the announcement. Some 340 employees will be let go, representing about 53% of the company. Most are in commercial and administrative roles, particularly ones related to Sage's approved drug for postpartum depression, Zulresso. Web17 ott 2024 · BOSTON, October 17, 2024—Karuna Pharmaceuticals, Inc (“Karuna”), focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders marked by psychosis and cognitive impairment, today announced the appointment of industry leader Jeff Jonas, MD, CEO of Sage Therapeutics (NASDAQ: SAGE), as an …
Sage Therapeutics Announces Chief Executive Jeff Jonas to
Web22 mar 2024 · To be marketed as Zulresso, it’s the first drug developed by and approved from Sage Therapeutics of Cambridge, Mass. Jeff Jonas, Sage’s CEO, recently chatted … WebJeff joined SAGE as CEO in 2013 and has more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the CNS field. Before joining the SAGE team, Jeff served as President of the Regenerative Medicine Division of Shire plc and previously as Senior Vice President of Research and … removal of ships boiler at 89th street
Sage Therapeutics Announces Chief Executive Jeff Jonas to …
Web27 apr 2024 · In March 2024, the FDA approved the first postpartum depression drug, developed by Sage Therapeutics. Led by CEO Jeff Jonas, Sage Therapeutics created the treatment by taking a different approach ... Web31 mar 2024 · I’m proud of the way our employees, partners, and the community have responded in this unprecedented time,” said Jeff Jonas, M.D., chief executive officer at Sage Therapeutics. “The teams at Sage are handling virtual work well, and progress across our pipeline remains strong. WebOn this week’s Tech Nation, it’s about developing medicines which enable the body to heal itself. First up, treating depression in a whole new way … and rapidly. Dr. Jeff Jonas, the Chief Innovation Officer and Director of Sage Therapeutics, talks about their drug Zuranolone, nearing the end of its drug approval journey. removal of scotus justice